{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:22:56Z","timestamp":1778750576382,"version":"3.51.4"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC)-associated ascites remain a therapeutic challenge, with bevacizumab showing limited efficacy due to resistance. Shengyang Shiyiwei Pill (SYP), a traditional Chinese medicine, may offer a multi-targeted approach, but its synergistic mechanisms with bevacizumab require investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In an H22-induced ascites model, we assessed SYP\u2013bevacizumab combination therapy by measuring survival, ascites volume, and molecular markers (VEGFA, CD31, Caspase-3). HepG2 cells were treated with SYP-containing serum to evaluate cell cycle arrest and ferroptosis (GPX4, iron levels). Network pharmacology identified SYP\u2019s bioactive compounds and potential targets, followed by bioinformatics validation (TNMplot, HCCDB) and molecular docking analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The SYP\u2013bevacizumab combination significantly reduced ascites volume and prolonged survival. Mechanistically, it downregulated VEGFA\/CD31 while upregulating Caspase-3. SYP induced G0\/G1-S phase-arrest and ferroptosis in HepG2 cells. Network pharmacology revealed quercetin and kaempferol as key active components targeting G6PD, with molecular docking confirming strong binding interactions. Bioinformatics analysis demonstrated that high G6PD expression correlated with poor HCC prognosis and immune cell infiltration. SYP restored sorafenib sensitivity in resistant cells through G6PD inhibition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>SYP enhances bevacizumab efficacy by targeting angiogenesis, ferroptosis, and G6PD-mediated resistance, providing a rationale for integrating traditional and modern therapies in HCC management. These findings highlight the value of network pharmacology in elucidating TCM mechanisms and support further clinical evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000004420","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T17:00:13Z","timestamp":1764003613000},"page":"290-302","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Synergistic mechanism of Shengyang Shiyiwei Pill in enhancing bevacizumab efficacy for hepatocellular carcinoma-associated ascites"],"prefix":"10.1097","volume":"88","author":[{"given":"Baiqing","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Oncology, Second Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuran","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Occupational and Radiological Health, Baotou Center for Disease Control and Prevention, Baotou, Inner Mongolia, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongli","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Oncology, Second Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyu","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Radiology, Second Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuiyu","family":"You","sequence":"additional","affiliation":[{"name":"Department of Oncology, Second Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heyi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Second Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Second Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengxin","family":"Bo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Second Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Second Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wulong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Second Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Second Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"R1-20260514","first-page":"229\u201363","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260514","doi-asserted-by":"crossref","first-page":"1966\u201374","DOI":"10.7150\/ijms.53743","article-title":"Development and validation a simple model for identify malignant ascites","volume":"18","author":"Guo","year":"2021","journal-title":"Int J Med Sci"},{"key":"R3-20260514","doi-asserted-by":"crossref","first-page":"533\u201342","DOI":"10.21873\/anticanres.16841","article-title":"Viscosity and characteristics of malignant ascites","volume":"44","author":"Maehara","year":"2024","journal-title":"Anticancer Res"},{"key":"R4-20260514","doi-asserted-by":"crossref","first-page":"910\u201317","DOI":"10.1007\/s10620-019-05537-2","article-title":"Disease burden of hepatocellular carcinoma: a global perspective","volume":"64","author":"Sayiner","year":"2019","journal-title":"Dig Dis Sci"},{"key":"R5-20260514","doi-asserted-by":"crossref","first-page":"1994\u20132002","DOI":"10.7150\/jca.91875","article-title":"Exploration of radiotherapy strategy for brain metastasis patients with driver gene positivity in lung cancer","volume":"15","author":"Bi","year":"2024","journal-title":"J Cancer"},{"key":"R6-20260514","doi-asserted-by":"crossref","first-page":"2179\u201388","DOI":"10.7150\/jca.69669","article-title":"Detecting the research trends and hot spots in external irradiation therapy for rectal cancer","volume":"13","author":"Bi","year":"2022","journal-title":"J Cancer"},{"key":"R7-20260514","first-page":"97","article-title":"Advances in the treatment of malignant ascites in China","volume":"32","author":"Zhang","year":"2024","journal-title":"Support Care Cancer"},{"key":"R8-20260514","doi-asserted-by":"crossref","first-page":"638\u201351","DOI":"10.1007\/s12072-020-10073-7","article-title":"Novel systemic therapy for hepatocellular carcinoma","volume":"14","author":"Dong","year":"2020","journal-title":"Hepatol Int"},{"key":"R9-20260514","doi-asserted-by":"crossref","first-page":"4636\u201342","DOI":"10.7150\/jca.95804","article-title":"Efficacy of whole-brain radiotherapy plus Simultaneous Integrated Boost (SIB-WBRT) for lung cancer brain metastases","volume":"15","author":"Bi","year":"2024","journal-title":"J Cancer"},{"key":"R10-20260514","doi-asserted-by":"crossref","first-page":"583\u2013604","DOI":"10.1142\/S0192415X24500253","article-title":"Traditional Chinese medicine for cancer treatment","volume":"52","author":"Liu","year":"2024","journal-title":"Am J Chin Med"},{"key":"R11-20260514","first-page":"40\u20133","article-title":"Study on the effect of Mongolian medicine Shengyang Shiyiwei Pill on a rat model of chronic renal failure","volume":"30","author":"Zhang","year":"2024","journal-title":"J Med Pharm Chin Minor"},{"key":"R12-20260514","first-page":"3","article-title":"Inhibitory effect of shengyangshiyiweiwan on proliferation of human three gastrointestinal carcinomas cells","volume":"20","author":"Deng","year":"2011","journal-title":"Chin J Ethnomed Ethnopharm"},{"key":"R13-20260514","doi-asserted-by":"crossref","first-page":"111660","DOI":"10.1016\/j.cellsig.2025.111660","article-title":"IGF2BP1\/AIFM2 axis regulates ferroptosis and glycolysis to drive hepatocellular carcinoma progression","volume":"130","author":"Peng","year":"2025","journal-title":"Cell Signal"},{"key":"R14-20260514","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s10555-025-10251-9","article-title":"Mitochondrial alterations and signatures in hepatocellular carcinoma","volume":"44","author":"Chen","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"R15-20260514","doi-asserted-by":"crossref","first-page":"15263","DOI":"10.3390\/ijms232315263","article-title":"New insights into Ferroptosis Initiating Therapies (FIT) by targeting the rewired lipid metabolism in ovarian cancer peritoneal metastases","volume":"23","author":"Zhan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R16-20260514","first-page":"5484976","article-title":"Identification of candidate biomarkers in malignant ascites from patients with hepatocellular carcinoma by iTRAQ-Based quantitative proteomic analysis","volume":"2018","author":"Zhang","year":"2018","journal-title":"Biomed Res Int"},{"key":"R17-20260514","first-page":"44","article-title":"Fra-1 affects chemotherapy sensitivity by inhibiting ferroptosis in gastric cancer cells","volume":"7","author":"Zeng","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"R18-20260514","doi-asserted-by":"crossref","first-page":"e70284","DOI":"10.1002\/cam4.70284","article-title":"Predictive prognostic model for hepatocellular carcinoma based on seven genes participating in arachidonic acid metabolism","volume":"13","author":"Gu","year":"2024","journal-title":"Cancer Med"},{"key":"R19-20260514","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41418-024-01406-2","article-title":"METTL3 confers oxaliplatin resistance through the activation of G6PD-enhanced pentose phosphate pathway in hepatocellular carcinoma","volume":"32","author":"Jin","journal-title":"Cell Death Differ 2024;"},{"key":"R20-20260514","doi-asserted-by":"crossref","first-page":"1599\u2013611","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"key":"R21-20260514","doi-asserted-by":"crossref","first-page":"1835\u201347","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"R22-20260514","doi-asserted-by":"crossref","first-page":"89\u2013101","DOI":"10.2174\/0115748928311077240424065832","article-title":"Development of a prognostic risk model based on oxidative stress-related genes for platinum-resistant ovarian cancer patients","volume":"20","author":"Su","year":"2025","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"R23-20260514","doi-asserted-by":"crossref","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol"},{"key":"R24-20260514","doi-asserted-by":"crossref","first-page":"203\u201322","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R25-20260514","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1038\/s41467-023-43462-1","article-title":"Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8(+) exhausted-like T cells","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"R26-20260514","doi-asserted-by":"crossref","first-page":"196\u2013202","DOI":"10.1016\/j.joim.2020.02.002","article-title":"Traditional Chinese medicine targeting cancer stem cells as an alternative treatment for hepatocellular carcinoma","volume":"18","author":"Tang","year":"2020","journal-title":"J Integr Med"},{"key":"R27-20260514","doi-asserted-by":"crossref","first-page":"469\u201377","DOI":"10.1016\/j.joim.2021.08.004","article-title":"Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: a focus on epithelial-mesenchymal transition","volume":"19","author":"Li","year":"2021","journal-title":"J Integr Med"},{"key":"R28-20260514","doi-asserted-by":"crossref","first-page":"1369110","DOI":"10.3389\/fimmu.2024.1369110","article-title":"Antitumor immunostimulatory activity of the traditional Chinese medicine polysaccharide on hepatocellular carcinoma","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"R29-20260514","doi-asserted-by":"crossref","first-page":"1183474","DOI":"10.3389\/fonc.2023.1183474","article-title":"Pan-cancer analysis reveals that G6PD is a prognostic biomarker and therapeutic target for a variety of cancers","volume":"13","author":"Zeng","year":"2023","journal-title":"Front Oncol"},{"key":"R30-20260514","doi-asserted-by":"crossref","first-page":"113417","DOI":"10.1016\/j.celrep.2023.113417","article-title":"Inhibiting G6PD by quercetin promotes degradation of EGFR T790M mutation","volume":"42","author":"Ge","year":"2023","journal-title":"Cell Rep"},{"key":"R31-20260514","doi-asserted-by":"crossref","first-page":"1120\u201333","DOI":"10.7150\/ijbs.65555","article-title":"High expression of G6PD increases doxorubicin resistance in triple negative breast cancer cells by maintaining GSH level","volume":"18","author":"Luo","year":"2022","journal-title":"Int J Biol Sci"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:00:57Z","timestamp":1778749257000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004420","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"2025-08-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}